SA
AZN icon

Shilanski & Associates’s AstraZeneca AZN Stock Holding History

Shilanski & Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,963
Closed -$215K – 98
2020
Q3 		$215K Buy
1,963
+14
+0.7% +$1.56K 0.15% 85
2020
Q2 		$206K Buy
+1,949
New +$201K 0.15% 81

Other funds holding AZN

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Shilanski & Associates's AZN Position: Q4 2020 in Review

Shilanski & Associates sold out of AstraZeneca (AZN) in Q4 2020, closing a stake of 1,963 shares — an estimated $215K sold.

Shilanski & Associates first reported a position in AZN in Q2 2020 and held it in 2 quarters. The position peaked at $215K in Q3 2020. 787 funds tracked by Wall St. Rank hold AZN as of Q4 2020.

  • Shilanski & Associates reported no remaining AstraZeneca position as of Q4 2020 after selling out during the quarter.
  • Shilanski & Associates sold 1,963 AstraZeneca shares in Q4 2020, an estimated $215K.
  • Shilanski & Associates first reported a position in AstraZeneca in Q2 2020 and held it in 2 quarters.
  • Shilanski & Associates's AstraZeneca position peaked at $215K in Q3 2020.
  • 787 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2020.

Based on Shilanski & Associates's 13F filing for Q4 2020, filed 3 Feb 2021.